AHEAD Medicine, an artificial intelligence (AI) health technology company, has added advancement in its flagship product, Cyto-Copilot, for acute myeloid leukaemia (AML) diagnosis.
Cyto-Copilot is an advanced AI-driven platform designed to advance the analysis of clinical flow cytometry data, independent of the flow cytometry panel or instrument used.
The machine learning-driven platform automates the analysis of cytometry data across various reagent and instrument platforms for disease classification and screening.
The new analysis module enables AML versus non-neoplastic diagnostic classification across five flow cytometry test panels and instruments.
AHEAD Medicine is set to showcase this development at the European Society of Clinical Cytometry Analysis (ESCCA) 2024 and International Clinical Cytometry Society (ICCS) 2024 conferences.
Cyto-Copilot integrates machine learning models and visualisation tools for efficient and consistent sample-level and cell-level classification. This reduces the workload for healthcare professionals during diagnostics.
The platform also helps lab staff triage cases through batch analysis, minimising the inconsistencies of manual processes, the AI HealthTech startup said.
This results in a streamlined workflow and improved diagnostic accuracy, enhancing patient outcomes and overall healthcare quality.
AHEAD Medicine develops AI-powered clinical data analysis solutions.
The company provides advanced data analytics for disease diagnosis, post-treatment monitoring, biomedical research, and quality assurance in cell therapy manufacturing.
The startup aims to improve patient outcomes and enhance clinical workflows.
AHEAD Medicine announced the AML upgrade in January during a poster presentation at the esteemed American Society of Hematology (ASH) 2023 Conference.
The ASH 2023 study examined the integration of diagnostic data from BD Biosciences and Beckman Coulter panels. These systems are popular in clinical and research environments.
Previously, AHEAD Medicine partnered with Mayo Clinic to improve AML patient care by boosting the performance of its cytometry platform.
In addition, the health technology firm collaborated with the University of Pittsburgh to create an AI-based blood cancer triage tool.
The tool streamlines flow cytometry data analysis, leading to faster and more accurate diagnoses.
